SAVA
Cassava Sciences Inc.
$2.87
+$0.24(+9.13%)
48
Overall
60
Value
36
Tech
--
Quality
Market Cap
$145.41M
Volume
1.91M
52W Range
$1.15 - $4.99
Target Price
$2.00
Company Overview
| Mkt Cap | $145.41M | Price | $2.87 |
| Volume | 1.91M | Change | +9.13% |
| P/E Ratio | -6.0 | Open | $2.88 |
| Revenue | -- | Prev Close | $2.63 |
| Net Income | $-24.3M | 52W Range | $1.15 - $4.99 |
| Div Yield | N/A | Target | $2.00 |
| Overall | 48 | Value | 60 |
| Quality | -- | Technical | 36 |
No chart data available
About Cassava Sciences Inc.
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest News
Cassava Sciences Reports Q3 2025 Financials and Advances Simufilam
TipRanks Auto-Generated Newsdesk•11 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SAVA | $2.87 | +9.1% | 1.91M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |